News

Ozempic's Effects Fade Fast After Discontinuation, New Studies Confirm

As demand for GLP-1 drugs surges, research reveals most patients regain weight and may experience withdrawal-like symptoms once off medication

• By Pooja S
• New Delhi
• Aug 01, 2025

News

In one of the largest analyses of its kind, scientists have confirmed that the weight loss produced by semaglutide-based medications such as Ozempic is largely reversed when the drug is discontinued. The peer-reviewed meta-analysis, published in BMC Medicine in July 2025, reviewed data from more than 6,300 adults across 11 randomized trials. It found that a significant proportion of lost weight—often more than half—returns within one year of stopping the drug, with a notable rebound beginning as early as eight weeks after cessation.

These findings underscore a fundamental limitation of GLP-1 receptor agonists like Ozempic: while they alter appetite regulation and metabolic function during treatment, these effects are not durable without continued dosing. In practical terms, this means that many patients who stop treatment are biologically predisposed to regain the weight they lost.

Weight Returns, Despite Lifestyle Efforts

According to the meta-analysis, people on GLP-1 receptor agonists regained an average of 2.5 kilograms within 20 weeks of stopping medication. In trials involving high-dose semaglutide (2.4 mg, branded as Wegovy), patients who had initially lost 15–17 kilograms often regained 9–10 kilograms over the following year. For many, this constituted a return to baseline body weight, despite the continued use of diet and exercise interventions.

This is consistent with results from the STEP-1 Extension Study (Wilding et al., DOM, 2022), which followed patients for one year after they stopped taking semaglutide. Participants regained two-thirds of their lost weight, and accompanying cardiometabolic improvements—such as reduced blood pressure and better blood glucose control—also declined.

In other words, both the weight loss and its physiological benefits are transient in the absence of ongoing pharmacological intervention.

How Semaglutide Alters Biology—Temporarily

Ozempic (semaglutide) is a synthetic analog of the gut hormone glucagon-like peptide-1 (GLP-1), which modulates insulin secretion, slows gastric emptying, and reduces appetite by acting on receptors in the pancreas, gut, and brain. During treatment, the drug dampens hunger and food-seeking behavior, which results in reduced caloric intake—often by 30 to 40 percent.

In the central nervous system, semaglutide targets GLP-1 receptors in the hypothalamus, particularly the arcuate nucleus and paraventricular nucleus, which regulate satiety and energy balance. It also suppresses activity in dopaminergic reward pathways, including the ventral tegmental area and nucleus accumbens, leading to diminished cravings and food-related reward.

However, as shown in fMRI imaging studies (van Bloemendaal et al., Diabetes, 2014), these effects are not sustained without active drug presence. When the drug is removed, there is a rebound in both ghrelin (the hunger hormone) and dopamine-based food reward signaling. Additionally, gastric emptying accelerates, reversing the satiety effect and enabling higher food intake.

Perhaps more critically, semaglutide triggers adaptive thermogenesis—a drop in resting metabolic rate that persists after weight loss. As shown in earlier studies (Rosenbaum & Leibel, NEJM, 2008), this metabolic suppression is not reversed when the weight returns. This means patients may need to consume fewer calories than before, just to maintain the same weight, making post-drug weight maintenance physiologically more difficult than baseline.

No Lasting Reset

Contrary to popular belief, there is no evidence that Ozempic “resets” the body’s weight set point. While some rodent studies have suggested longer-term metabolic reprogramming via hypothalamic pathways, human trials show that the benefits fade quickly once treatment ends. The BMC Medicine review explicitly concludes that GLP-1 drugs do not offer sustained weight regulation post-discontinuation unless accompanied by continuous therapy.

This challenges narratives that semaglutide might be used as a time-limited intervention. "These medications do not cure obesity—they suppress its symptoms as long as the drug is present," said one of the lead authors. "Once you stop, the biology resumes its baseline state."

Concerns Over Neurological and Psychiatric Effects

Emerging data is also raising red flags about the neurological and psychiatric impact of GLP-1 agonists. A 2024 study in Nature Scientific Reports that analyzed more than 240,000 electronic health records found a statistically significant increase in new diagnoses of depression, anxiety, and suicidal ideation among users of GLP-1 drugs compared to matched non-users.

Specifically, semaglutide users had a 1.72-times higher risk of psychiatric disorders, and the risk of documented suicidal thoughts was 2.4 times greater. Though the authors cautioned that causality cannot yet be proven, the findings prompted calls for long-term neuropsychiatric monitoring of GLP-1 drug users—especially those using them off-label for cosmetic weight loss.

Meanwhile, case reports and anecdotal evidence from patients describe emotional blunting, loss of interest in previously pleasurable activities, and social withdrawal while on the drug—effects some liken to low-level anhedonia.

Safety Questions Persist

Ozempic’s side effect profile extends beyond its neurological effects. Gastrointestinal symptoms remain the most common adverse effects, with nausea, vomiting, and diarrhea reported in up to 40 percent of users during the first weeks of treatment. More serious concerns include:

• Gastroparesis (stomach paralysis), a debilitating condition now under FDA investigation;
• Pancreatitis, though data remains mixed;
• Gallbladder disease, particularly with rapid weight loss;
• Possible increased risk of macular degeneration, as suggested by recent observational studies;
• Medullary thyroid carcinoma risk, based on rodent studies—though human relevance is unclear.

Despite limited long-term safety data, semaglutide is now widely prescribed for obesity in non-diabetic adults, often in younger populations without serious comorbidities.

A Costly, Lifelong Intervention?

With monthly costs exceeding $1,000 in many countries, semaglutide is not only biologically short-lived but also financially unsustainable for many patients. Without insurance coverage, long-term adherence becomes a barrier—leading to sudden discontinuation, rapid weight regain, and possible psychological effects from perceived “failure.”

This presents an ethical dilemma: prescribing a medication whose benefits require indefinite use, but which is priced and supplied as if it were short-term.

As GLP-1 agonists continue to dominate obesity treatment globally, the evidence base is also growing clearer. These drugs may offer powerful short-term benefits—but they do not cure obesity, do not permanently change metabolism, and may carry underrecognized neurological and psychiatric risks.

For patients and clinicians alike, the message is sobering: the cost of stopping Ozempic is not just biological—it may be behavioral, metabolic, and psychological as well.